By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Accept
Privacy Policy

Discover updates to RELiZORB and what they mean for your patients #

#
Upcoming Educational Programs
#
RELiZORB (iMMOBILIZED lipase) cartridge

Improve Every Feed From the Outside In

RELiZORB is designed to hydrolyze fats as formula flows through the cartridge, so essential fatty acids are ready to absorb before they even reach your patient’s gastrointestinal (GI) tract1

RELiZORB is the only FDA-cleared enzyme product that breaks down fats in enteral formula1,2

Compatible with a broad list of formulas and easily connects with bolus and continuous setups1,3

Compatible with a broad list of formulas and easily connects with bolus and continuous setups

How RELiZORB works1

  • Mimics the function of the pancreatic digestive enzyme lipase
    • Only lipase can hydrolyze fats into fatty acids and accounts for a majority of fatty acid digestion
  • Facilitates absorption of essential fatty acids and monoglycerides prior to entering your patient’s body

Lipase is covalently bound to the small white beads inside the cartridge

When formula enters RELiZORB, fats in their triglyceride forms, including LCTs, are hydrolyzed.

#

Fatty acids, such as omega-3 (DHA and EPA), are released in their free fatty acid and monoglyceride forms and are available to be absorbed.

The lipase-bead complex iLipase® (iMMOBILIZED lipase) is retained during use by 2 filters within the cartridge as enteral formula flows through.

See RELiZORB results

Proven to hydrolyze available fats, including medium-chain and long-chain triglycerides (MCTs and LCTs)1,4

  • LCTs are complex and contain essential fatty acids
  • Compared to MCTs, LCTs are harder to hydrolyze but provide ~10% more calories
  • Intended to provide continuous fat hydrolysis throughout the entire feed
#

RELiZORB’s range of configurations and ease of use allow it to become a quick and integral part of each tube feed to meet the nutritional needs of your patients, such as those with short bowel syndrome (SBS) and cystic fibrosis (CF).1,5

With a new design come new features1

The new design comes with new features

Learn more about the updated RELiZORB cartridge

#

Formula compatibility

Greater compatibility puts fat hydrolysis at your fingertips.1,3,*

Ready to use with your patient’s tube-feeding setup, RELiZORB offers expanded compatibility with formulas, including some formulas containing insoluble fiber.

Click to see a list of RELiZORB-compatible formulas and pumps.

Dive deeper into our FAQs

RELiZORB expert case-study videos

In these videos, a team of clinical experts explores issues associated with fat malabsorption and how RELiZORB may help address these challenges in patients who require tube feeding.

RELiZORB expert case-study videos - Kay Vavrina

Cystic fibrosis

13-year-old female with pancreatic insufficiency

Kay Vavrina, BS, MPA, RD, LD, CNSC

RELiZORB expert case-study videos - Melissa Wallinga

Critical care

6-year-old GJ-tube–dependent male admitted to the pediatric ICU

Melissa Wallinga, MS, RD, CSPCC, LD

RELiZORB expert case-study videos - Whitney Christe, 70-year-old male with pancreatic cancer and pancreaticoduodenectomy

Oncology

70-year-old male with pancreatic cancer and pancreaticoduodenectomy

Whitney Christie, MS, RD, CSO, CNSC

RELiZORB expert case-study videos - Whitney Christe, 73-year-old with pancreatic cancer and pancreatectomy

Oncology

73-year-old male with pancreatic cancer and pancreatectomy

Whitney Christie, MS, RD, CSO, CNSC

RELiZORB expert case-study videos - Jaclyn Moore

Oncology + pancreatitis

73-year-old male with nasopharyngeal squamous cell carcinoma and pancreatitis

Jaclyn Moore, MS, RD, CSO

#

Oncology

84-year-old male diagnosed with pancreatic adenocarcinoma

Jaclyn Moore, MS, RD, CSO

See clinical results with RELiZORB

Study results

DHA=docosahexaenoic acid; EPA=eicosapentaenoic acid.

*Please see list of compatible formulas and hydrolysis information.

References: 1. RELiZORB. Instructions for use. Alcresta Therapeutics, Inc; 2023. 2. Alcresta Therapeutics announces FDA expanded use clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for pediatric patients ages 2 to 5 years. News release. Alcresta Therapeutics, Inc; August 31, 2023. 3. RELiZORB formulas. Alcresta Therapeutics, Inc; 2023. Accessed November 28, 2023. https://relizorb.com/formulas 4. Shah ND, Limketkai BN. The use of medium-chain triglycerides in gastrointestinal disorders. Practical Gastroenterol. 2017;41(2):20-28. 5. Freedman S, Orenstein D, Black P, et al. Increased fat absorption from enteral formula through an in-line digestive cartridge in patients with cystic fibrosis.  J Pediatr Gastroenterol Nutr. 2017;65(1):97-101. doi:10.1097/MPG.0000000000001617

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Warnings
  • RELiZORB is for use with enteral feeding only.
See more
#

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Warnings
  • RELiZORB is for use with enteral feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral formula or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, enteral formula leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral formulas compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for manual bolus by syringe (push or gravity). A detailed listing of formulas, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • Do not use excessive force when using RELiZORB with enteral syringe push feeding methods.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding.
  • Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.